NCT05284539View on ClinicalTrials.gov

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

760

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

October 10, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab

Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER